Wheatgrass — Research Profile

What the Research Says

Evidence for wheatgrass is preliminary and mixed. The 2002 distal-ulcerative-colitis trial randomized 23 people and reported improved bleeding and disease-activity scores over one month; small numbers and incomplete data limit confidence. The 2017 lipid trial in 59 women found changes in selected biomarkers versus no intervention, without establishing disease prevention.

For thalassemia, the 2004 before-and-after pilot suggested lower transfusion needs in some of 16 patients. A 2009 study found no significant reduction, and the 2018 randomized 69-child study also found no between-group reduction in transfusion number or requirement. Its reported liver, spleen, and quality-of-life changes were largely within-group findings and should not be presented as clear superiority over control.

The 2007 chemotherapy study was a 60-patient prospective matched-control pilot; it requires confirmation and does not justify self-treatment during cancer care. The Shakya glucose study was in diabetic rats, not people. Laboratory antioxidant activity and chlorophyll content are not evidence for a clinical detox, predictable energy benefit, or a mechanism that builds human blood.

Benefits of Wheatgrass

• Ulcerative colitis — a 2002 trial randomized 23 people to 100 mL juice or placebo daily for one month. Disease-activity and bleeding scores improved, but full information was available for only 19 people; larger studies are needed.
• Thalassemia — an uncontrolled 16-patient pilot suggested reduced transfusion requirements in some participants. A later 69-child randomized study found no difference in transfusion number or blood requirement between groups. These findings do not support replacing transfusions or other treatment.
• Blood lipids — a 59-woman trial of 3.5 g/day for ten weeks reported lower total cholesterol, triglycerides, and Apo B versus no intervention. This is limited biomarker evidence, not proof of cardiovascular benefit.
• Blood sugar — the Shakya study examined diabetic rats. It does not establish improved glucose control or a treatment dose in people.
• Composition — nutrient content depends on the preparation and serving size. Chlorophyll resembling part of hemoglobin does not show that ingesting it builds blood.

Side Effects and Safety

Safety profile: Generally Safe

Potential Side Effects

• Nausea and gastrointestinal intolerance have been reported; symptoms are not evidence of detoxification.
• Wheat or grass allergy requires particular caution; a gluten-free claim does not make a product safe for wheat allergy.
• Fresh or home-grown preparations can carry microbial or mold contamination; product hygiene matters.
• Pregnancy, breastfeeding, and prolonged high-dose use have not been adequately studied.

Drug & Supplement Interactions

• Warfarin — changes in vitamin K-containing foods or supplements can affect anticoagulation; discuss regular use with the prescribing team.
• Diabetes medicines, immunosuppressants, and cancer treatment — interaction evidence is limited. Discuss use with the treating clinician rather than assuming either a proven interaction or compatibility.
• Iron-overload disorders — evaluate the actual product composition and treatment plan; wheatgrass is not a substitute for prescribed chelation or other care.